The novel tellurium immunomodulator AS101 inhibits interleukin-10 production and p38 MAPK expression in atopic dermatitis

Dvora Sredni-Kenigsbuch; Michael Shohat; Batia Shohat; Dan Ben-Amitai; Chi Chao Chan; Michael David

doi:10.1016/j.jdermsci.2007.12.007

The novel tellurium immunomodulator AS101 inhibits interleukin-10 production and p38 MAPK expression in atopic dermatitis

Dvora Sredni-Kenigsbuch^*, Michael Shohat, Batia Shohat, Dan Ben-Amitai, Chi Chao Chan, Michael David

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

Abstract

The immunomodulator, AS101, inhibits production of IL-10, IL-4 and expression of p38 MAPK, while increasing production of IFNγ and IL-2. Together with its excellent clinical safety profile in humans, suggests a potential therapeutic use for AD.

Original language	English
Pages (from-to)	232-235
Number of pages	4
Journal	Journal of Dermatological Science
Volume	50
Issue number	3
DOIs	https://doi.org/10.1016/j.jdermsci.2007.12.007
State	Published - Jun 2008
Externally published	Yes

Access to Document

10.1016/j.jdermsci.2007.12.007

Cite this

@article{0e05eb85583648b89c745de4e7ab3feb,

title = "The novel tellurium immunomodulator AS101 inhibits interleukin-10 production and p38 MAPK expression in atopic dermatitis",

abstract = "The immunomodulator, AS101, inhibits production of IL-10, IL-4 and expression of p38 MAPK, while increasing production of IFNγ and IL-2. Together with its excellent clinical safety profile in humans, suggests a potential therapeutic use for AD.",

author = "Dvora Sredni-Kenigsbuch and Michael Shohat and Batia Shohat and Dan Ben-Amitai and Chan, {Chi Chao} and Michael David",

year = "2008",

month = jun,

doi = "10.1016/j.jdermsci.2007.12.007",

language = "אנגלית",

volume = "50",

pages = "232--235",

journal = "Journal of Dermatological Science",

issn = "0923-1811",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - The novel tellurium immunomodulator AS101 inhibits interleukin-10 production and p38 MAPK expression in atopic dermatitis

AU - Sredni-Kenigsbuch, Dvora

AU - Shohat, Michael

AU - Shohat, Batia

AU - Ben-Amitai, Dan

AU - Chan, Chi Chao

AU - David, Michael

PY - 2008/6

Y1 - 2008/6

N2 - The immunomodulator, AS101, inhibits production of IL-10, IL-4 and expression of p38 MAPK, while increasing production of IFNγ and IL-2. Together with its excellent clinical safety profile in humans, suggests a potential therapeutic use for AD.

AB - The immunomodulator, AS101, inhibits production of IL-10, IL-4 and expression of p38 MAPK, while increasing production of IFNγ and IL-2. Together with its excellent clinical safety profile in humans, suggests a potential therapeutic use for AD.

UR - http://www.scopus.com/inward/record.url?scp=42649142595&partnerID=8YFLogxK

U2 - 10.1016/j.jdermsci.2007.12.007

DO - 10.1016/j.jdermsci.2007.12.007

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

AN - SCOPUS:42649142595

SN - 0923-1811

VL - 50

SP - 232

EP - 235

JO - Journal of Dermatological Science

JF - Journal of Dermatological Science

IS - 3

ER -

The novel tellurium immunomodulator AS101 inhibits interleukin-10 production and p38 MAPK expression in atopic dermatitis

Abstract

Access to Document

Other files and links

Fingerprint

Cite this